Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study

• Published in: Glycoconjugate journal Vol. 33; no. 4; pp. 599 - 606
• Main Authors: Gurecka, Radana, Koborova, Ivana, Csongova, Melinda, Sebek, Jozef, Sebekova, Katarina
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2016; Springer Nature B.V
• Subjects: Adolescent; Amine Oxidase (Copper-Containing) - blood; Biochemistry; Biomarkers; Biomarkers - blood; Biomedical and Life Sciences; Cell Adhesion Molecules - blood; Diabetes; Female; Heart Diseases - blood; Humans; Life Sciences; Male; Obesity; Obesity - blood; Original Article; Pathology; Proteins; Receptor for Advanced Glycation End Products - blood; Risk Factors; Microinflammation; sVAP-1; Obesity; Cardiometabolic risk factors; sRAGE; Adolescents; esRAGE
• DOI: 10.1007/s10719-016-9696-9
• ISSN: 0282-0080; 1573-4986

In non-diabetics, low levels of soluble receptor for advanced glycations end products (sRAGE) associate with an increased risk of development of diabetes, cardiovascular afflictions, or death. The majority of studies in non-diabetics report an inverse relationship between measures of obesity, cardiometabolic risk factors and sRAGE and/or endogenous secretory RAGE (esRAGE) levels. To elucidate whether this inconsistency is related to the metabolically healthy obese phenotype, or a different impact of the risk factors in presence and absence of obesity, we analyzed data from 2206 apparently healthy adolescents (51 % girls) aged 15-to-19 years. The association of sRAGE levels with soluble vascular adhesion protein-1/semicarbazide sensitive amine oxidase (sVAP-1/SSAO) was also investigated. Centrally obese, including metabolically healthy, adolescents present significantly lower sRAGE and esRAGE, but not sVAP-1, levels in comparison with their lean counterparts. An increasing number of cardiometabolic risk factors did not associate with significant changes in sRAGE, esRAGE or sVAP-1 levels either in lean or in obese subjects. In multivariate analyses, WHtR, hsCRP, markers of glucose homeostasis, renal function, adiponectin, and sVAP-1 associated significantly with sRAGE and esRAGE. SVAP-1 correlated significantly with glycemia, adiponectin, hsCRP, and sRAGE. Thus, in adolescents, a decline in sRAGE and esRAGE precedes the development of metabolic syndrome. When combined, standard and non-standard cardiometabolic risk factors explain only minor proportion in a variability of sRAGE and esRAGE (8 %–11 %); or sVAP-1 (12 %–20 %). Elucidation of pathogenetic mechanisms underlying early decline in sRAGE and esRAGE levels in obese adolescents and their clinical impact with regard to future cardiometabolic health requires further studies.